BIAFW
bioAffinity Technologies, Inc. WarrantstockNASDAQWarrant
addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.15 | 2026-11-12 | +31.31% | 0.000 |
| 1M | 0.42 | 2026-10-22 | -52.82% | 8.557 |
| 3M | 0.12 | 2026-08-19 | +58.84% | 5.549 |
| 6M | 0.22 | 2026-05-19 | -10.15% | 5.563 |
| 1Y | 0.27 | 2025-11-17 | -25.38% | 2.891 |
| 2Y | 0.64 | 2024-11-19 | -69.10% | — |
| 5Y | 2.10 | 2022-09-01 | -90.58% | -0.153 |
bioAffinity Technologies, Inc. Warrant (NASDAQ:BIAFW) stock price today is $0.20, and today's volume is 275. BIAFW is up 31.308% today. The 30 day average volume is 2,692. BIAFW market cap is $316,649 with 1.60M shares outstanding.